N.J. Elmiron Eye Damage Actions Designated as Multicounty Litigation



DOCUMENTS
  • Notice to the Bar


TRENTON, N.J. — The New Jersey Supreme Court has designated actions alleging the bladder cyst drug Elmiron causes eye damage as multicounty litigation for centralized management purposes.

According to a Feb. 10 notice, the cases filed in counties across New Jersey will be sent to the Bergen County (N.J.) Superior Court and assigned to Judge Rachelle Harz, who will oversee management and trial issues and may return the actions to their original counties for disposition.

Defendants in the actions include Johnson & Johnson, Janssen Research & Development LLC, Janssen Ortho LLC, and Ortho-McNeil Pharmaceuticals LLC.

The FDA approved Elmiron in …






UPCOMING CONFERENCES




HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation Conference

January 10, 2025 - Long Beach, CA
The Westin Long Beach

MORE DETAILS



HarrisMartin's New Jersey Asbestos Litigation Conference

February 27, 2025 - New Brunswick, NJ
Hyatt Regency New Brunswick

MORE DETAILS